[{"orgOrder":0,"company":"Cessatech","sponsor":"Proveca","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2024","type":"Licensing Agreement","leadProduct":"Ketamine Hydrochloride","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Cessatech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Cessatech \/ Proveca","highestDevelopmentStatusID":"14","companyTruncated":"Cessatech \/ Proveca"}]

Find Clinical Drug Pipeline Developments & Deals by Cessatech

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Compamed
                          Not Confirmed
                          Compamed
                          Not Confirmed

                          Details : Under the agreement, Proveca will be the marketing authorization holder of CT001 worldwide excluding the US, which is being evaluated in the late stage for the treatment of Acute Pain in children.

                          Brand Name : CT001

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          August 26, 2024

                          Lead Product(s) : Ketamine Hydrochloride,Sufentanil Citrate

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase II/ Phase III

                          Sponsor : Proveca

                          Deal Size : Undisclosed

                          Deal Type : Licensing Agreement

                          blank